Narodny ustav detskych chorob

Running trials

• Recruiting

  A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

  2022-502365-26-00· Phase 3· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Source

• Recruiting

  Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

  NCT07220252· Phase 2/3· Source

• Recruiting

  A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  NCT06941272· Phase 1/2· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· Source

• Recruiting

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Phase 1/2· Source

• Recruiting

  A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

  NCT05748171· Phase 2· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Source

• Recruiting

  Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis

  2024-511686-11-00· Phase 3· Source

• Active, not recruiting

  Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

  NCT04624230· Phase 3· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Recruiting

  International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

  NCT04043494· Phase 3· Source

• Recruiting

  Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

  NCT03643276· Phase 3· Source

• Recruiting

  A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies

  2023-504880-18-00· Phase 1/2· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Phase 2· Source

• Active, not recruiting

  Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

  NCT01892722· Phase 3· Source

• Recruiting

  Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

  NCT01949129· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers8 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Neuroblastoma3 recruiting
• Asthma1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

  NCT06321601· Phase 3· Source

• Active, not recruiting

  A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

  NCT05970172· Phase 3· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Source

• Recruiting

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  NCT04779320· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

  NCT03958877· Phase 3· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Source